Ecallantide

In plain language

Ecallantide is an injected drug for hereditary angioedema (HAE), a genetic condition where attacks of deep tissue swelling can block the airway. It is sold as Kalbitor.

HAE attacks are driven by too much bradykinin, a swelling molecule. Ecallantide blocks kallikrein, the enzyme that produces bradykinin, stopping the attack. Because some patients react badly to the protein itself, it carries a boxed warning for allergic reactions and must be given by a healthcare provider.

For students

Ecallantide is a 60-residue recombinant protein (about 7,054 Da) based on Kunitz-type protease inhibitors, engineered by phage display (Dyax) to bind plasma kallikrein with high affinity (K_i about 36 pM). In HAE type I and II (C1-inhibitor deficiency), kallikrein activation proceeds unchecked, generating bradykinin via high-molecular-weight kininogen cleavage.

The EDEMA0 and EDEMA1 trials (randomized, placebo-controlled; EDEMA1 n=96) showed significant improvement in mean symptom severity at 4 hours, supporting approval in 2009. Because anaphylaxis occurred in about 3% of treated patients (with hypersensitivity in up to 4%), the drug carries a boxed warning and is administered subcutaneously by a healthcare professional with observation, which limits its market position relative to self-administered HAE agents like icatibant and C1-inhibitor concentrates.

For researchers and instructors

Biochemistry. Kunitz-domain engineering by phage display is the foundational lesson: a naturally occurring protein scaffold (aprotinin-like) was diversified and selected for kallikrein specificity, an early showcase of directed protein evolution as a drug discovery platform.

Pharmacology. 30 mg subcutaneous injection in three 10 mg/1 mL sites; onset within 1-4 hours; boxed warning for anaphylaxis mandates supervised administration; repeated dosing within 24 hours is permitted.

Human evidence. EDEMA0 (n=56) and EDEMA1 (n=96) randomized trials showed significant symptom improvement at 4 hours; long-term open-label data (EDEMA4) support repeat-use safety.

Teaching point. Teaches the trade-off between engineered specificity and immunogenicity in protein drugs, and how administration restrictions can limit an effective medicine.